Purpose: The ability of silver nanoparticles (AgNPs) of different sizes to influence copper metabolism in mice is assessed. Materials and Methods: AgNPs with diameters of 10, 20, and 75 nm were fabricated through a chemical reduction of silver nitrate and characterized by UV/Vis spectrometry, transmission and scanning electronic microscopy, and laser diffractometry. To test their bioactivity, Escherichia coli cells, cultured A549 cells, and C57Bl/6 mice were used. The antibacterial activity of AgNPs was determined by inhibition of colony-forming ability, and cytotoxicity was tested using the MTT test (viability, %). Ceruloplasmin (Cp, the major mammalian extracellular copper-containing protein) concentration and enzymatic activity were measured using gel-assay analyses and WB, respectively. In vitro binding of AgNPs with serum proteins was monitored with UV/Vis spectroscopy. Metal concentrations were measured using atomic absorption spectrometry. Results: The smallest AgNPs displayed the largest dose- and time-dependent antibacterial activity. All nanoparticles inhibited the metabolic activity of A549 cells in accordance with dose and time, but no correlation between cytotoxicity and nanoparticle size was found. Nanosilver was not uniformly distributed through the body of mice intraperitoneally treated with low AgNP concentrations. It was predominantly accumulated in liver. There, nanosilver was included in ceruloplasmin, and Ag-ceruloplasmin with low oxidase activity level was formed. Larger nanoparticles more effectively interfered with the copper metabolism of mice. Large AgNPs quickly induced a drop of blood serum oxidase activity to practically zero, but after cancellation of AgNP treatment, the activity was rapidly restored. A major fraction of the nanosilver was excreted in the bile with Cp. Nanosilver was bound by alpha-2-macroglobulin in vitro and in vivo, but silver did not substitute for the copper atoms of Cp in vitro. Conclusion: The data showed that even at low concentrations, AgNPs influence murine copper metabolism in size-dependent manner. This property negatively correlated with the antibacterial activity of AgNPs.
The present study assesses copper metabolism of the host organism as a target of antiviral strategy, basing on the “virocell” concept. Silver nanoparticles (AgNPs) were used as a specific active agent because they reduce the level of holo-ceruloplasmin, the main extracellular cuproenzyme. The mouse model of influenza virus A infection was used with two doses: 1 LD50 and 10 LD50. Three treatment regimens were used: Scheme 1—mice were pretreated 4 days before infection and then every day during infection development; Scheme 2—mice were pretreated four days before infection and on the day of virus infection; Scheme 3—virus infection and AgNP treatment started simultaneously, and mice were injected with AgNPs until the end of the experiment. The mice treated by Scheme 1 demonstrated significantly lower mortality, the protection index reached 60–70% at the end of the experiment, and mean lifespan was prolonged. In addition, the treatment of the animals with AgNPs resulted in normalization of the weight dynamics. Despite the amelioration of the infection, AgNP treatment did not influence influenza virus replication. The possibility of using nanosilver as an effective indirectly-acting antiviral drug is discussed.
Silver nanoparticles (AgNPs) of various sizes and shapes are widely used because of their antibacterial properties. However, their bioactivity in mammals is insufficiently investigated. The aim of the present study was to assess the effect of AgNPs' shape on their antibacterial activity, cytotoxicity, and ability to interfere in copper metabolism in mice. For this, AgNPs with the same linear size (75 nm), but different shape (spherical and quasi-spherical), were fabricated by chemical reduction from silver nitrate. The test of the biological activity of AgNPs showed that both types of particles suppressed bacterial (E. coli) and mammalian (A549) cell growth in a time- and dose-dependent manner. Quasi-spherical AgNPs had stronger antibacterial activity (several orders of magnitude) than the spherical AgNPs. In mice, the intake, distribution and accumulation of silver from AgNPs depending on the administration method were compared and intraperitoneal injections were chosen as the most appropriate. Silver concentration in organs of mice and its distribution in the organs did not depend on the shape of AgNPs. During the 7 days of intraperitoneal treatment with AgNPs, the silver concentration in blood serum increased, while the copper concentration and ceruloplasmin (Cp) oxidase activity (measured by the o-dianisidine in-gel assay) decreased. At the same time, the Cp protein concentration determined by immunoblotting did not change. Analysis of the blood serum by gel-filtration has shown that blood serum silver was associated with Cp and with a larger protein, presumably α-2-macroglobulin. After the AgNP injections were cancelled, the organs and the blood serum were cleared from silver through bile, while the copper concentration and Cp oxidase activity of blood serum recovered to their normal levels. So, the correlation between particle shape and their biological activity was observed. Quasi-spherical AgNPs having more edges possessed higher antibacterial activity. At the same time, both types of AgNPs lowered the copper status of blood serum in mice in a similar manner. In the article, the potential danger of AgNP's low doses for mammals, including humans, and the specificity of the nanosilver turnover in the mammalian body, which suggests that AgNPs can be used for safe treatment, are discussed.
The link between copper metabolism and tumor progression motivated us to use copper chelators for suppression of tumor growth. We assume that silver nanoparticles (AgNPs) can be used for lowering bioavailable copper. Our assumption is based on the ability of Ag(I) ions released by AgNPs in biological media and interfere with Cu(I) transport. Intervention of Ag(I) into copper metabolism leads to the replacement of copper by silver in ceruloplasmin and the decrease in bioavailable copper in the bloodstream. To check this assumption, mice with ascitic or solid Ehrlich adenocarcinoma (EAC) were treated with AgNPs using different protocols. Copper status indexes (copper concentration, ceruloplasmin protein level, and oxidase activity) were monitored to assess copper metabolism. The expression of copper-related genes was determined by real-time PCR in the liver and tumors, and copper and silver levels were measured by FAAS. Intraperitoneal AgNPs treatment beginning on the day of tumor inoculation enhanced mice survival, reduced the proliferation of ascitic EAC cells, and suppressed the activity of HIF1α, TNF-α and VEGFa genes. Topical treatment by the AgNPs, which was started together with the implantation of EAC cells in the thigh, also enhanced mice survival, decreased tumor growth, and repressed genes responsible for neovascularization. The advantages of silver-induced copper deficiency over copper chelators are discussed.
The aim of the study is the modern scientific literature estimation in the field of the investigation of neurodegenerative and metabolic disorders mediated by the trace amines and their receptors. The analysis of modern ideas about the feedback of neurodegenerative and metabolic diseases in which the trace amines and their receptors are involved was carried out. The important role of trace amines and their receptors in the regulation of the dopamine system, in connection with metabolic and neurodegenerative diseases, including Parkinsons disease, ADHD, schizophrenia, obesity, metabolic syndrome and other pathological conditions, has been shown. Trace amines and their receptors have a direct effect on dopamine systems, being regulators of various metabolic and neurodegenerative processes, participating in energy metabolism, neurogenesis, and other vital processes.
This study identified an oxidase-positive protein in the plasma membrane fraction of the C. elegans N2 strain. The protein with a molecular weight of approximately 85 kDa reacted with antibodies against human and mouse, but not rat, ceruloplasmin and exhibited oxidase activity. Bioinformatic analysis revealed that the F21D5.3 protein possesses four copper-binding sites, similar to those in other multicopper oxidases (MCOs), and plastocyanin-like domains characteristic of MCOs. However, neither an iron-binding domain nor ferroxidase activity, typical features of MCOs, were detected through in silico analysis and or in-gel assays. Despite the absence of ferroxidase activity, these findings suggest that the protein may be the product of the F21D5.3 gene, an ortholog of MCOs in C. elegans. Heat map analysis indicated F21D5.3 expression in the entero-rectal valve cells and both the anterior and posterior intestines. Among the genes associated with copper transport, only cua-1 exhibited a similar expression pattern. In the C. elegans cua-1H828Q strain, which mimics a mutation in human ATP7B linked to Wilson’s disease (WD), oxidase activity was also observed. Notably, both strains showed reduced oxidase activity when cultured with silver nanoparticles (AgNPs). These findings highlight the potential of the cua-1H828Q strain as a model for studying copper and iron metabolism and for developing therapeutic strategies for WD.